AMPK, insulin resistance, and the metabolic syndrome
AMPK, insulin resistance, and the metabolic syndrome
复制标题
DOI：
10.1172/jci67227
复制
发表时间：
2013-07-01
影响因子：
15.9
通讯作者：
Cacicedo, Jose M.
中科院分区：
文献类型：
--
作者：
Ruderman, Neil B.;Carling, David;Cacicedo, Jose M.
胰岛素抵抗（IR）和高胰岛素血症是代谢综合征的标志，如中心性肥胖、血脂异常和易患2型糖尿病、动脉粥样硬化性心血管疾病、高血压和某些癌症。长期以来，人们一直知道定期锻炼和热量限制可以增加胰岛素敏感性并降低这些疾病的患病率。随后对AMP活化蛋白激酶（AMPK）的鉴定及其在运动和燃料剥夺中的活化导致了对AMPK对IR和代谢综合征相关疾病的影响的研究。在这篇综述中，我们评估了这方面的文献，特别强调的假设，即AMPK的失调是这些疾病在人类的致病因素和目标，其预防和治疗。
Insulin resistance (IR) and hyperinsulinemia are hallmarks of the metabolic syndrome, as are central adiposity, d.yslipidemia, and a predisposition to type 2 diabetes, atherosclerotic cardiovascular disease, hypertension, and certain cancers. Regular exercise and calorie restriction have long been known to increase insulin sensitivity and decrease the prevalence of these disorders. The subsequent identification of AMP-activated protein kinase (AMPK) and its activation by exercise and fuel deprivation have led to studies of the effects of AMPK on both IR and metabolic syndrome-related diseases. In this review, we evaluate this body of literature, with special emphasis on the hypothesis that dysregulation of AMPK is both a pathogenic factor for these disorders in humans and a target for their prevention and therapy.